C-erbB-2与KRAS基因在结直肠癌中的表达及其相互关系

The C-erb B-2 and KRAS expression and their correlation in colorectal cancer

目的探讨C-erbB-2与KRAS基因在结直肠癌中的表达及其相互关系,为判断患者预后及潜在的药物作用靶点提供理论依据。方法对238例结直肠癌组织蜡块进行回顾性研究,采用FISH法检测C-erbB-2扩增情况,采用实时荧光定量PCR法检测KRAS的突变情况,分析其与临床病理特征之间的关系。结果结直肠癌中C-erbB-2总扩增率为1.7%(4/238),KRAS总突变率为32.3%(88/238);C-erbB-2扩增与年龄、性别、肿瘤发生部位、组织学分型、分化程度、淋巴结转移、Duke′s分期及浸润深度无关(P> 0.05);KRAS突变与淋巴结转移及Duke′s分期有关(P <0.05),而与其他病理参数均无关(P> 0.05);C-erbB-2与KRAS二者表达呈正相关关系。结论结直肠癌中发生、发展过程中C-erbB-2扩增与KRAS的突变二者具有协同作用,联合检测二者可为判断患者预后及靶向治疗的潜在靶点提供理论依据。

Objective To investigate the C-erbB-2 and KRAS gene expression in colorectal cancer and to reveal their correlations in prognosis and theoretical basis of drug targets. Methods Total of 238 tissues and pathological features were collected from colorectal cancer cases. FISH was used to detect the C-erbB-2 amplification, and qRT-PCR was used to detect KRAS mutations situation. Results In colorectal cancer,C-erbB-2 amplification rate was 1.7%( 4/238), KRAS mutation rate was 32.3%( 88/238). C-erbB-2 augmentation showed no relationships with age,sex,tumor location,differentiation,lymph node metastasis,D uke′s stages and infiltration depth(all P > 0.05);KRAS mutations associated with lymph node metastasis and Duke′s stage(P < 0.05), but have nothing to do with other pathological parameters(P > 0.05);C-erbB-2 was positively related to KRAS. Conclusion C-erbB-2 amplification and KRAS mutations have synergy to occurrence and development of colorectal cancer.